GT Biopharma Reports Director Changes and Officer Compensation
Ticker: GTBP · Form: 8-K · Filed: Aug 29, 2025 · CIK: 109657
Sentiment: neutral
Topics: director-change, officer-compensation
TL;DR
GT Biopharma swapped a director and is adjusting exec pay. Keep an eye on this.
AI Summary
GT Biopharma, Inc. filed an 8-K on August 26, 2025, reporting the departure of director Dr. Jonathan M. Roth and the election of new director Dr. David L. Smith. The filing also disclosed compensatory arrangements for certain officers, though specific details and dollar amounts were not provided in this excerpt.
Why It Matters
Changes in board composition and executive compensation can signal shifts in company strategy or governance, potentially impacting investor confidence and future performance.
Risk Assessment
Risk Level: medium — Director changes and undisclosed compensatory arrangements introduce uncertainty about the company's internal dynamics and future financial commitments.
Key Players & Entities
- GT Biopharma, Inc. (company) — Registrant
- Dr. Jonathan M. Roth (person) — Departing Director
- Dr. David L. Smith (person) — Newly Elected Director
FAQ
Who is the departing director and when did their departure become effective?
Dr. Jonathan M. Roth is the departing director, with the earliest event reported as August 26, 2025.
Who is the newly elected director?
Dr. David L. Smith has been elected as a new director.
What is the exact date of the report?
The exact date of the report is August 26, 2025.
What is GT Biopharma's state of incorporation?
GT Biopharma, Inc. is incorporated in Delaware.
What other items are covered in this 8-K filing besides director changes?
This 8-K filing also covers the election of directors and compensatory arrangements of certain officers.
Filing Stats: 632 words · 3 min read · ~2 pages · Grade level 11.2 · Accepted 2025-08-29 16:15:35
Key Financial Figures
- $0.001 — nge on which registered Common stock, $0.001 par value GTBP The Nasdaq Stock Mar
Filing Documents
- form8-k.htm (8-K) — 40KB
- ex10-1.htm (EX-10.1) — 20KB
- 0001493152-25-012479.txt ( ) — 225KB
- gtbp-20250826.xsd (EX-101.SCH) — 3KB
- gtbp-20250826_lab.xml (EX-101.LAB) — 33KB
- gtbp-20250826_pre.xml (EX-101.PRE) — 22KB
- form8-k_htm.xml (XML) — 4KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. GT BIOPHARMA, INC. Date: August 29, 2025 By: /s/ Alan Urban Alan Urban Chief Financial Officer